AndreaBozzo/ceres-open-data-index huggingface dataset:
Comparison of deferral rates using a computerized versus written blood donor questionnaire: a randomized, cross-over study [ISRCTN84429599]

Background
          Self-administered computer-assisted blood donor screening strategies may elicit more accurate responses and improve the screening process.
        
        
          Methods
          Randomized crossover trial comparing responses to questions on a computerized hand-held tool (HealthQuiz, or HQ), to responses on the standard written instrument (Donor Health Assessment Questionnaire, or DHAQ). Randomly selected donors at 133 blood donation clinics in the area of Hamilton, Canada participated from 1995 to 1996. Donors were randomized to complete either the HQ or the DHAQ first, followed by the other instrument. In addition to responses of 'yes' and 'no' on both questionnaires, the HQ provided a response option of 'not sure'. The primary outcome was the number of additional donors deferred by the HQ.
        
        
          Results
          A total of 1239 donors participated. Seventy-one potential donors were deferred as a result of responses to the questionnaires; 56.3% (40/71) were deferred by the DHAQ, and an additional 43.7% (31/71) were deferred due to risks identified by the HQ but not by the DHAQ. Fourteen donors self-deferred; 11 indicated on the HQ that they should not donate blood on that day but did not use the confidential self-exclusion option on the DHAQ, and three used the self-exclusion option on the DHAQ but did not indicate that they should not donate blood on the HQ. The HQ identified a blood contact or risk factor for HIV/AIDS or sexually transmitted infection that was not identified by the DHAQ in 0.1% to 2.7% of donors.
        
        
          Conclusion
          A self-administered computerized questionnaire may increase risk reporting by blood donors.
Primary biliary cirrhosis and autoimmune cholangitis are not associated with coeliac disease in Crete

Background
          An increased prevalence of coeliac disease in patients with primary biliary cirrhosis has been recently reported. However, in other studies the association has not been confirmed. There have been no formal attempts to systematically evaluate patients with autoimmune cholangitis for coeliac disease.
        
        
          Methods
          Sera from 62 patients with primary biliary cirrhosis, 17 with autoimmune cholangitis and 100 blood donors were screened for anti-gliadin, anti-endomysial, anti-reticulin, and IgA class antibodies to guinea pig liver-derived tissue transglutaminase. Eighteen untreated coeliacs served as methodological controls. Analyses were performed by using the χ2 and Fischer's exact tests.
        
        
          Results
          Anti-gliadin antibodies were detected in 21% of patients with primary biliary cirrhosis, 35% of patients with autoimmune cholangitis, and 3% of controls (p < 0.001). IgA class gliadin antibodies positivity was more pronounced in patients with Scheuer's stage III-IV disease (p < 0.05). Anti-transglutaminase antibodies were detected in 10% and in 18% of patients with primary biliary cirrhosis and autoimmune cholangitis respectively (p < 0.001). Anti-reticulin and anti-endomysial antibodies were negative in all patients. Duodenal biopsies were performed in 59% and 71% of patients with primary biliary cirrhosis and autoimmune cholangitis respectively, tested positive for at least one antibody class. No histological features of coeliac disease were found.
        
        
          Conclusions
          We were unable to demonstrate an increased risk of coeliac disease in patients with primary biliary cirrhosis and autoimmune cholangitis. Our results confirm the previously reported high prevalence of false-positive anti-gliadin and guinea pig liver-derived anti-tissue transglutaminase antibodies in patients with chronic liver disease.
Compound 530440: 4-Ethylbenzoic acid, undecyl ester

Chemical compound data from PubChem database. IUPAC Name: undecyl 4-ethylbenzoate. Molecular Formula: C20H32O2. Molecular Weight: 304.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Molecular cloning and tissue distribution of mammalian L-threonine 3-dehydrogenases

Background
          In mammals, L-threonine is an indispensable amino acid. The conversion of L-threonine to glycine occurs through a two-step biochemical pathway involving the enzymes L-threonine 3-dehydrogenase and 2-amino-3-ketobutyrate coenzyme A ligase. The L-threonine 3-dehydrogenase enzyme has been purified and characterised, but the L-threonine 3-dehydrogenase gene has not previously been identified in mammals.
        
        
          Results
          Transcripts for L-threonine 3-dehydrogenase from both the mouse and pig are reported. The ORFs of both L-threonine dehydrogenase cDNAs encode proteins of 373 residues (41.5 kDa) and they share 80% identity. The mouse gene is located on chromosome 14, band C. The amino-terminal regions of these proteins have characteristics of a mitochondrial targeting sequence and are related to the UDP-galactose 4-epimerases, with both enzyme families having an amino-terminal NAD+ binding domain. That these cDNAs encode threonine dehydrogenases was shown, previously, by tiling 13 tryptic peptide sequences, obtained from purified L-threonine dehydrogenase isolated from porcine liver mitochondria, on to the pig ORF. These eukaryotic L-threonine dehydrogenases also have significant similarity with the prokaryote L-threonine dehydrogenase amino-terminus peptide sequence of the bacterium, Clostridium sticklandii. In murine tissues, the expression of both L-threonine dehydrogenase and 2-amino-3-ketobutyrate coenzyme A ligase mRNAs were highest in the liver and were also present in brain, heart, kidney, liver, lung, skeletal muscle, spleen and testis.
        
        
          Conclusions
          The first cloning of transcripts for L-threonine dehydrogenase from eukaryotic organisms are reported. However, they do not have any significant sequence homology to the well-characterised Escherichia coli L-threonine dehydrogenase.
Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES

The present invention provides a method of treating prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I) wherein R<SUP>1 </SUP>and R<SUP>2 </SUP>are each independently hydrogen or C<SUB>1</SUB>-C<SUB>4 </SUB>alkyl; or a pharmaceutically acceptable salt thereof. In a second embodiment, the invention provides a method of treating androgen-independent prostatic adenocarcinoma comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof. In a third embodiment, the invention provides a method of treating an AKT-mediated disease selected from the group consisting of glioblastoma, colon cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and renal cell cancer, comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
Compound 526911: 2-Isopentoxyethyl trifluoroacetate

Chemical compound data from PubChem database. IUPAC Name: 2-(3-methylbutoxy)ethyl 2,2,2-trifluoroacetate. Molecular Formula: C9H15F3O3. Molecular Weight: 228.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528184: 1,3-Cyclopentadiene, 5-heptyl

Chemical compound data from PubChem database. IUPAC Name: 5-heptylcyclopenta-1,3-diene. Molecular Formula: C12H20. Molecular Weight: 164.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400144-T1: [Translated] MEDIATION WITH DISTRIBUTED PROTECTION

A system for responding to failures of connections in a network. A system for responding to destination failures involving SPVx connections. A system for responding to source failures involving SPVx connections A system for responding to failures involving SPVx connections. A method for responding to failures involving SPVx connections. A method for responding to destination failures involving SPVx connections. A method for responding to source failures involving SPVx connections. A method for responding to failures of connections in a network.
HAICViz - iSA

<p>The healthcare-associated infection component of CDC’s <a href="https://www.cdc.gov/ncezid/dpei/eip/index.html" target="_blank">EIP</a> engages a <a href="https://www.cdc.gov/ncezid/dpei/eip/eip-sites.html" target="_blank">network</a> of state health departments and their academic medical center partners to help answer critical questions about emerging HAI threats, advanced infection tracking methods, and antibiotic resistance in the United States. Information gathered through this activity will play a key role in shaping future policies and recommendations targeting HAI prevention. Click <a href="https://www.cdc.gov/hai/eip/saureus.html" target="_blank">here</a> to learn more about Invasive Staphylococcus aureus infections</p>

<h3>Interpretation</h3>
<ul><li>Data presented in HAICViz may differ from other HAIC publications since different datasets or methods may be used.</li><li>Small numbers for some topics or filters may make year to year changes difficult to interpret.</li><li>Since each infection may have unique characteristics, the information available to display differs by individual organism.</li></ul>

<h3>More Details</h3>
<ul><li><a href="https://www.cdc.gov/hai/eip/saureus.html#Methods" target="_blank">Methodology</a>: Find details about surveillance population, case determination, surveillance evaluation, and more.</li><li>Reports and Findings: Access <a href="https://www.cdc.gov/hai/eip/saureus.html#anchor_1611155585754" target="_blank">reports</a> or lists of <a href="https://www.cdc.gov/hai/eip/saureus.html#anchor_1611155777037" target="_blank">publications</a> using HAIC Invasive Staphylococcus aureus data</li></ul>
Bupropion hydrochloride

Bupropion Hydrochloride is a generic prescription medication available as extended-release tablets in 100mg, 150mg, and 200mg strengths for oral use. Manufactured by Aurobindo Pharma Limited, it acts as an aminoketone that increases dopamine and norepinephrine activity, commonly used to treat depression. This information was generated using AI and is provided for informational and research purposes only.
Compound 527739: Propyl 2,3-dichloropropanoate

Chemical compound data from PubChem database. IUPAC Name: propyl 2,3-dichloropropanoate. Molecular Formula: C6H10Cl2O2. Molecular Weight: 185.05. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526810: 18-Hydroxy-arachidic, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 18-[tert-butyl(dimethyl)silyl]oxyicosanoate. Molecular Formula: C27H56O3Si. Molecular Weight: 456.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2010 State Profile — Wisconsin

This state profile includes data from facilities in Wisconsin that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Wisconsin. In Wisconsin, 250 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 17,385 clients in substance abuse treatment on March 31, 2010. The survey response rate in Wisconsin was 87.7%.
Compound 526681: 1-[4-(Nitromethyl)phenyl]propan-2-amine

Chemical compound data from PubChem database. IUPAC Name: 1-[4-(nitromethyl)phenyl]propan-2-amine. Molecular Formula: C10H14N2O2. Molecular Weight: 194.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528426: Tetrapropylene glycol monopropyl ether

Chemical compound data from PubChem database. IUPAC Name: 1-[1-[1-(1-propoxypropan-2-yloxy)propan-2-yloxy]propan-2-yloxy]propan-2-ol. Molecular Formula: C15H32O5. Molecular Weight: 292.41. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Table 1. Illicit Drug Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs

Table 1. Illicit Drug Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs
National Health and Nutrition Examination Survey (NHANES) Restricted Data: Prior to 1999

The <b> National Health and Nutrition Examination Survey</b> (NHANES) is designed to assess the health and nutritional status of adults and children in the United States. The survey is unique in that it combines interviews with standardized physical examinations and laboratory tests. <br>
NHANES was conducted on a periodic basis from 1971 to 1994, including NHANES I (1971-1975), NHANES II (1976-1980), NHANES III (1988-1994), and a Hispanic Health and Nutrition Examination Survey (HHANES, 1982-1984). In 1999, NHANES became continuous and has been collecting data annually ever since. <br>
All of the NHANES programs utilized a stratified, multistage probability cluster design to provide a nationally representative sample of the U.S. civilian, noninstitutionalized population. The NHANES interview includes demographic, socioeconomic, dietary, and health-related questions. The examination component conducted in a mobile examination center consists of medical, dental, and physiological measurements, as well as the collection of biospecimens, such as blood and urine for laboratory testing.

This set of restricted data contains indirect identifying and/or sensitive information collected in <b>NHANES prior to 1999. </b>Please refer to the links below for additional data available from NHANES:
<ul><li><a href="https://wwwn.cdc.gov/nchs/nhanes/Default.aspx">NHANES Public Use Data at: https://wwwn.cdc.gov/nchs/nhanes/Default.aspx</a></li>
<li><a href="https://data.cdc.gov/dataset/National-Health-and-Nutrition-Examination-Survey-N/9ixb-fwvy">NHANES Restricted Data: 1999 - present at: https://data.cdc.gov/dataset/National-Health-and-Nutrition-Examination-Survey-N/9ixb-fwvy</a></li>
<li><a href="https://data.cdc.gov/dataset/National-Health-and-Nutrition-Examination-Survey-N/hdx4-e4uu">NHANES Genetic Restricted Data at: https://data.cdc.gov/dataset/National-Health-and-Nutrition-Examination-Survey-N/hdx4-e4uu</a></li>
<li><a href="https://data.cdc.gov/dataset/3-NHANES-National-Youth-Fitness-Survey-NNYFS-Restr/5u84-m4rs">NHANES National Youth Fitness Survey (NNYFS) Restricted Data at: https://data.cdc.gov/dataset/3-NHANES-National-Youth-Fitness-Survey-NNYFS-Restr/5u84-m4rs</a></li> </ul>
Please refer to the <a href="https://www.cdc.gov/nchs/nhanes/index.htm">NHANES - National Health and Nutrition Examination Survey Homepage at: https://www.cdc.gov/nchs/nhanes/index.htm</a> for further details on the NHANES design, implementation, and data analysis.
Supporting Evidence-Based Home Visitation Programs to Prevent Child Abuse and Neglect Project: St. Vincent Mercy Medical Center Foundation

Location:

Lucas County, Ohio

Home Visiting Program Selected:

Healthy Families America

Home Visiting Target Population:

Families with children between 3-5 years old

Project Overview:
St. Vincent Mercy Medical Center will collaborate with Lucas County Children's Services, Lucas County Family Council, Children's Trust Fund, Northwest Ohio Family and Child Abuse Prevention Center and other Federal, State and local programs to develop a comprehensive child maltreatment prevention strategy. This collaborative group will leverage multiple funding streams to provide home visiting services. The planned project, Healthy Connections Home Visitation Project, will implement an enhanced Healthy Families America model. Planned enhancements will address existing concerns that partner violence, parent substance use, and depression are not adequately addressed if paraprofessional home visitors are not comfortable addressing these issues by: (1) using bachelor and master-prepared home visitors with expertise in substance use, maternal depression, and/or partner violence and (2) assigning home visitors to families based on their primary area of risk. St. Vincent will evaluate their project through a randomized control evaluation that compares the enhanced HFA model to usual care.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526380: 1,3,6-Tribromo,2-chloro-dibenzo-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,3,6-tribromo-2-chlorodibenzo-p-dioxin. Molecular Formula: C12H4Br3ClO2. Molecular Weight: 455.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Table 15. Perceptions of Great Risk from Smoking One or More Packs of Cigarettes per Day, by Age Group and State: Percentages, Annual Averages Based on 2013 and 2014 NSDUHs

Table 15. Perceptions of Great Risk from Smoking One or More Packs of Cigarettes per Day, by Age Group and State: Percentages, Annual Averages Based on 2013 and 2014 NSDUHs
Compound 525091: 1,3-Dichloroisopropyl hexanoate

Chemical compound data from PubChem database. IUPAC Name: 1,2-dichloropropan-2-yl hexanoate. Molecular Formula: C9H16Cl2O2. Molecular Weight: 227.12. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400258-T1: [Translated] TRANSDERMAL BUPRENORPHINE DOSING SCHEME FOR PAIN RELIEF

Dosage regimens of buprenorphine achieving rapid pain relief without increasing nausea, vomiting, or other adverse effects, are described. Also described are buprenorphine dosage regimens for treating chronic pain comprising administering to the patient (1) a first buprenorphine-containing transdermal dosage form for a first dosing period that is no more than about 5 days; (2) a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than 5 days, the second dosage form comprising the same dosage of buprenorphine as, or a greater dosage of buprenorphine than, the first dosage form; and (3) a third buprenorphine-containing transdermal dosage form for a third dosing period, the third dosage form comprising a greater dosage of buprenorphine than the second dosage form.
Preoperative prediction of pediatric patients with effusions and edema following cardiopulmonary bypass surgery by serological and routine laboratory data

Aim
          Postoperative effusions and edema and capillary leak syndrome in children after cardiac surgery with cardiopulmonary bypass constitute considerable clinical problems. Overshooting immune response is held to be the cause. In a prospective study we investigated whether preoperative immune status differences exist in patients at risk for postsurgical effusions and edema, and to what extent these differences permit prediction of the postoperative outcome.
        
        
          Method
          One-day preoperative serum levels of immunoglobulins, complement, cytokines and chemokines, soluble adhesion molecules and receptors as well as clinical chemistry parameters such as differential counts, creatinine, blood coagulation status (altogether 56 parameters) were analyzed in peripheral blood samples of 75 children (aged 3–18 years) undergoing cardiopulmonary bypass surgery (29 with postoperative effusions and edema within the first postoperative week).
        
        
          Results
          Preoperative elevation of the serum level of C3 and C5 complement components, tumor necrosis factor-α, percentage of leukocytes that are neutrophils, body weight and decreased percentage of lymphocytes (all P < 0.03) occurred in children developing postoperative effusions and edema. While single parameters did not predict individual outcome, >86% of the patients with postoperative effusions and oedema were correctly predicted using two different classification algorithms. Data mining by both methods selected nine partially overlapping parameters. The prediction quality was independent of the congenital heart defect.
        
        
          Conclusion
          Indicators of inflammation were selected as risk indicators by explorative data analysis. This suggests that preoperative differences in the immune system and capillary permeability status exist in patients at risk for postoperative effusions. These differences are suitable for preoperative risk assessment and may be used for the benefit of the patient and to improve cost effectiveness.
Quinapril hcl and hydrochlorothiazide

Quinapril HCl and Hydrochlorothiazide is a prescription medication combining an ACE inhibitor and a diuretic to treat high blood pressure. Available as oral tablets in strengths like 10mg/12.5mg, 20mg/12.5mg, and 20mg/25mg, it's manufactured by Lupin Pharmaceuticals under ANDA076374. This information was generated using AI and is provided for informational and research purposes only.
Antinociceptive and anti-inflammatory effects of

Background
          Crocus sativus L. (saffron) is used in folk medicine, for example as an antiedematogenic agent. We aimed to evaluate the antinociceptive and anti-inflammatory activity of saffron extracts in mice.
        
        
          Results
          We used aqueous and ethanolic maceration extracts of Crocus sativus L. stigma and petals. Antinociceptive activity was examined using the hot plate and writhing tests. The effect of extracts against acute inflammation was studied using xylene induced ear edema in mice. The activity of the extracts against chronic inflammation was assessed by formalin-induced edema in the rat paw. In the hot plate tests, intraperitoneal injection of both extracts showed no significant antinociceptive activity in mice. The extracts exhibited antinociceptive activity against acetic acid induced writhing. Naloxone partially blocked only the antinociceptive activity of the stigma aqueous extract. Only the stigma extracts showed weak to moderate effect against acute inflammation. In chronic inflammation, both aqueous and ethanolic stigma extracts, as well as ethanolic petal extract, exerted anti-inflammatory effects.
        
        
          Conclusions
          We conclude that aqueous and ethanolic extracts of saffron stigma and petal have an antinociceptive effect, as well as acute and/or chronic anti-inflammatory activity.